Skip to content
Search

Latest Stories

Morningside Pharmaceuticals' Nik Kotecha named in top 50 most ambitious business leaders list

Dr Nik Kotecha, chairman of Morningside Pharmaceuticals, has been named in the LDC’s Top 50 Ambitious Business Leaders for 2021 list.

The list, which is supported by The Times, recognises and celebrates inspiring leaders from among the UK’s most successful and fast-growing businesses. Now in its fourth year, the 2021 programme was said to have received 600 nominations from across a diverse range of sectors.


Dr Kotecha’s Loughborough-based Morningside Pharmaceuticals was set up in the early 90s as a manufacturer and supplier of generic medicines to the UK and international export markets. Today, the company has over 240 generic and branded licenced medicines in the UK and EU, delivered twice daily to the NHS.

He is also chairman of the Randal Charitable Foundation which has contributed over £9m to significantly improve the lives of people in the UK and globally since it was established in 2017.

In his reaction to being included in a prestigious programme, Dr Kotecha said: “It is a great privilege and an honour to make this national list alongside so many talented business leaders and entrepreneurs.

"One of my passions is working with young entrepreneurs to help them develop the necessary skills and experience to create the success stories of tomorrow. I hope my story and experiences can inspire and encourage others to try new things and follow their entrepreneurial dreams.”

More For You

First daily pill for endometriosis to be available on NHS

Instead of travelling to clinics for injections, endometriosis patients can take a daily tablet at home

Getty Images

New endometriosis pill approved for NHS use, but only few patients will benefit

The National Institute for Health and Care Excellence (NICE) has approved a new pill for the treatment of endometriosis, providing hope for thousands of women affected by the debilitating condition.

The pill, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), is the first long-term daily pill approved for use in the UK to treat endometriosis, and it is expected to help about 1,000 patients every year.

Keep ReadingShow less
​RPS urges its members and fellows to vote in favour of Royal College for “a stronger, louder voice”

The Special Resolution Vote will remain open until 5 p.m. on Thursday, 24 March 2025.

Getty Images

Royal College voting begins: A historic moment in the profession’s evolution

Becoming a royal college will ensure pharmacy profession gains the recognition and authority it deserves, says RPS president Professor Claire Anderson.

Starting today (13), members and fellows of the Royal Pharmaceutical Society (RPS) will begin voting on the proposed changes to its Royal Charter, marking the beginning of a historic shift toward becoming the Royal College of Pharmacy.

Keep ReadingShow less
GPs to play crucial role in transforming Wales’ health service

Jeremy Miles

(Photo credit: www.gov.wales )

Strengthening GPs’ role key to transforming healthcare - Jeremy Miles

Welsh health secretary Jeremy Miles has recognised the need to transform health services and bring healthcare closer to home.

Speaking at the recent Welsh Local Medical Committees Conference, he emphasised that strengthening the role of GPs would be crucial in improving patient healthcare and tackling NHS waiting lists.

Keep ReadingShow less
NPA and IPA urge NHS England to release pharmacy economic analysis immediately

Pharmacy bodies call for transparency on the funding gap amid ongoing contract negotiations.

Getty Images

Pharmacy bodies demand immediate release of economic analysis

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) have jointly written to NHS England, demanding the immediate release of the independent economic analysis of pharmacy finances commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

Keep ReadingShow less